Impact of Active Antihyperglycemic Components as Herbal Therapy for Preventive Health Care Management of Diabetes

Author(s): Harsha Kashyap, Sarika Gupta*, Renu Bist.

Journal Name: Current Molecular Medicine

Volume 19 , Issue 1 , 2019

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Diabetes is a metabolic hyperglycemic condition that progressively develops, effect small and large sensory fibers in the affected population. It has various complications as hypertension, coronary artery disease, stroke, blindness, kidney disease as well as peripheral neuropathy. Sulfonylureas, thiazolidinediones, metformin, biguanidine, acarbose and insulin are commonly used drugs for diabetic patients, but these all have certain side effects. Even metformin, that is known as the miracle drug for diabetes has been found to be associated with side effects, as during treatment it involves complications with eyes, kidneys, peripheral nerves, heart and vasculature. In the present article, we hypothesize recent discoveries with respect to active ingredients from Indian medicinal plants i.e., polypeptide-p (protein analogue act as artificial insulin), charantin (a steroidal saponin), momordicin (an alkaloid) and osmotin (ubiquitous plant protein and animal analogue of human adeponectin) possessing anti-hyperglycemic potential for diabetes type II. Therefore, plants as herbal therapy have preventive care of hyperglycemia accompanied with healthy lifestyle which can provide significant decline in the incidences of diabetes in future.

Keywords: Diabetes, diabetic neuropathy, anti-hyperglycemic, preventive health care management, diacylglycerol, herbal therapy.

[1]
Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: Global estimates of diabetes prevalence for 2017 and projections for 2945. Diabetes Res Clin Pract 2018; 132: 271-81.
[2]
Loghami ES. Nutritional therapy for overweight children and adolescents with type 2 diabetes. Curr Diab Rep 2015; 5: 385-90.
[3]
Lakshmi SM, Rani SS, Reddy TUK. A review on diabetes melletus and the herbal plants used for its treatment. Asian J Pharm Clin Res 2012; 5: 15-21.
[4]
Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther 2008; 88: 1322-35.
[5]
Volpe CMO, Delfino PHV, Anjos PMF, Machado JAN. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis 2018; 9: 1-6.
[6]
Nayak A, De S. Anti Diabetic Potential Medicinal Plants. BioMedRx 2013; 1: 32-46.
[7]
Thornicroft G, Alem A, Santos RAD, et al. WPA guidance on steps, obstacles and mistakes to avoid in the implementation of community mental health care. World Psychiatry 2010; 9: 67-77.
[8]
Atlanta GA. National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States. Centers for Disease Control and Diabetes 2011; pp. 1-12.
[9]
Joseph B, Jini D. Antidiabetic Effects of Momordica charantia (bitter melon) and its medcal potency. Asian Pac J Trop Med 2013; 3: 93-102.
[10]
Seaquist ER. How does diabetes affect the brain? American Diabetes Association 2010; 59: 4-5.
[11]
Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90.
[12]
Sai Y, Tsuji A. Transporter-mediated drug delivery: Recent progress and experimental approaches. Drug Discov Today 2004; 9: 712-20.
[13]
Rizza RA. Pathogenesis of Fasting and Postprandial Hyperglycemia in Type 2 Diabetes: Implications for Therapy. Diabetes 2010; 59: 2697-707.
[14]
Singh S. Type 2 diabetes pharmacoepidemiology update 2014: Safety versus efficacy. Curr Diab Rep 2014; 14: 1-6.
[15]
Oberg M, Jaakkola MS, Woodward A, Peruga A, Prüss-Ustün A. Worldwide burden of disease from exposure to second-hand smoke: A retrospective analysis of data from 192 countries. Lancet 2011; 377: 139-46.
[16]
Seaquist ER. How does diabetes affect the brain? American Diabetes Association 2010; 59: 4-5.
[17]
Gaddam A, Galla C, Thummiseti S, Marikant RK, Palanisamy UD, Rao PV. Role of fenugreek in the prevention of type 2 diabetes mellitus in prediabetes. J Diabetes Metab Disord 2015; 14: 2-10.
[18]
Yadav M, Kha KK, Beg MZ. Medicinal plants used for the treatment of diabetes by the baiga tribe living in rewa district m.p. IJLS 2012; 2: 99-102.
[19]
Dwivedi C, Daspaul S. Antidiabetic herbal drugs and polyherbal formulation used for diabetes: A review. The Journal of Phytopharmocology 2013; 2: 44-51.
[20]
Shukla R, Sharma SB, Puri D, Prabhu KM, Murthy PS. Medicinal plants for treatment of diabetes mellitus. Indian J Clin Biochem 2000; 15: 169-77.
[21]
Bordoloi R, Dutt KN. A review on herbs used in the treatmment of diabetes mellitus. J Pharm Chem Biol Sci 2014; 2: 86-92.
[22]
Korczowski MM. Dietary control of diabetes: Reality or myth? South Med J 1985; 78: 979-86.
[23]
Ajabnoor MA, Tilmisany AK. Effect of trigonella foenumgraecum on blood glucose levels in normal and alloxan-diabetic mice. J Ethnopharmacol 1988; 22: 45-9.
[24]
Yoshikawa M, Murakami T, Shimada H, et al. Salacinol, potent antidiabetic principle with unique thiosugarsulfoniumsulfate structure from the ayurvedic traditional medicine salaciareticulata in sri lanka and india. Tetrahedron Lett 1997; 38: 8367-70.
[25]
Bailey CJ, Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care 1989; 12: 553-64.
[26]
Luo J, Fort DM, Carlson TJ, et al. Cryptolepissanguinolenta: An ethnobotanical approach to drug discovery and the isolation of a potentially useful new antihyperglycemic agent. Diabet Med 1998; 15: 367-74.
[27]
Ernst E. Plants with hypoglycemic activity in humans. Phytomedicine 1997; 4: 73-8.
[28]
Wanq CH, Lin PC, Lee YT, Chuanq CW, Tsay SL, Chu CY. Using a nurse invented t-bar device in a rehabilation program improved the range of motion for rotator cuff repair patients. J Clin Nurs 2012; 21(1-2): 121-8.
[29]
Kuhn TS. The Structure of Scientific Revolutions. The University of Chicago Press: Chicago 1970.
[30]
Assaad FF. Weeds and men: What genomes teach us about plant cell biology. Curr Opin Plant Biol 2001; 4: 478-87.
[31]
Ryan CA, Pearce G, Scheer J, Moura DS. Polypeptide hormones. Plant Cell 2002; 14: S251-64.
[32]
Jonak C, Hirt H. Glycogen synthase kinase 3/ shaggy-like kinases in plants: An emerging family with novel functions. Trends Plant Sci 2002; 7: 457-61.
[33]
Malviya N, Jain S, Malviya S. Antidiabetic potential of medicinal plants. Acta Poloniae Pharmaceutica-. Drug Res 2010; 67(2): 113-8.
[34]
Laskowski M, Haessler HA, Miech RP, Peanasky RJ, Laskowski M. Effect of trypsin inhibitor on passage of insulin across the intestinal barrier. Science 1958; 127: 1115-6.
[35]
Oliveira AEA, Machado OLT, Gomes VM, et al. Jack bean seed coat contains a protein with complete sequence homology to bovine insulin. Protein Pept Lett 1999; 6: 15-21.
[36]
Oliveira AEA, Sassaki GL, Iacomini M, et al. Isolation and characterization of a galactorhamnan polysaccharide from the seed coat of Canavaliaensiformis that is toxic to the cowpea weevil (Callosobruchusmaculatus). Entomol Exp Appl 2001; 101: 225-31.
[37]
Oldham S, Hafen E. Insulin/IGF and target of rapamycin signalling: A tor de force in growth control. Trends Cell Biol 2003; 13: 79-85.
[38]
Zick Y. Insulin resistance: A phosphorylation-based uncoupling of insulin signalling. Trends Cell Biol 2001; 11: 437-41.
[39]
Smit AB, Van Kesteren RE, Li KW, et al. Towards understanding the role of insulin in the brain: Lessons from insulin-related signalling systems in the invertebrate brain. Prog Neurobiol 1998; 54: 35-54.
[40]
Jarald E, Joshi SB, Jain DC. Diabetes and herbal medicines. Iranian Journal of Pharmacology and Therapeutics 2008; 7: 97-106.
[41]
Pfeiffer AHF, Klein HH. The treatment of type 2 diabetes. Dtsch Arztebl Int 2014; 111: 69-82.
[42]
Tiwari P. Recent trends in therapeutic approaches for diabetes management: A comprehensive update. J Diabetes Res 2015; 2015: 1-11.
[43]
Atansov AG, Waltenberger B, Pferschy-Wenzig EM, et al. Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnol Adv 2015; 33: 1582-614.
[44]
Hemmings BA. Restuccia. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 2012; 4: 1-3.
[45]
Khanna P, Jain SC, Panagariya A, Dixit VP. Hypoglycemic activity of Polypeptide-P from a plant source. J Nat Prod 1981; 44: 648-55.
[46]
Singh J, Cumming E, Manoharan G, Kalasz H, Adeghate E. Medicinal chemistry of the anti-diabetic effects of Momordica charantia: active constituents and modes of actions. Open Med Chem J 2011; 5: 70-7.
[47]
Grover JK, Vats V, Yadav S. Effect of feeding aqueous extract of Pterocarpusmarsupium on glycogen content of tissues and the key enzymes of carbohydrate metabolism. Mol Cell Biochem 2002; 241: 53-9.
[48]
Singh NK, Bracker CA, Hasegawa P, Handa AK. Characterization of osmotin: A thaumatin-like protein associated with osmotic adaptation in plant cells. Plant Physiol 1987; 85: 529-36.
[49]
Singh NK, Bracker CA, Hasegawa P, Handa AK. Characterization of osmotin: A thaumatin-like protein associated with osmotic adaptation in plant cells. Plant Physiol 1987; 85: 529-36.
[50]
Marles RJ. Farnsworth. Antidiabetic plants and their active constituents. Phytomedicine 1995; 2: 137-89.
[51]
Naseer MI, Ullah I, Narasimhan ML, et al. Neuroprotective effect of osmotin against ethanol-induced apoptotic neurodegeneration in the developing rat brain. Cell Death Dis 2014; 5: e1150.
[52]
Narasimhan ML, Coca MA, Jin J, et al. Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol Cell 2005; 17: 171-80.
[53]
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes and the metabolic syndrome. J Clin Invest 2006; 116: 1784-92.
[54]
Iwabu M, Iwabu MO, Yamauchi T. Kadowaki. Adiponectin/adiponectin receptor in disease and aging. Aging Mech Dis 2015; 13: 1-6.
[55]
Kumar SA, Kumari PH, Kumar GS, Mohanalatha C, Kishor PBK. Osmotin: A plant sentinel and a possible agonist of mammalian adiponecin. Mol Cell 2015; 6: 1-16.
[56]
Ali T, Yoon GH, Shah SA, Lee HY, Kim MO. Osmotin attenuates amyloid beta-induced memory impairment, tau phosphorylation and neurodegeneration in the mouse hippocampus. Sci Rep 2015; 5: 1-17.
[57]
Trivedi VR, Chorawala MR, Shah GB. Osmotin: A new adiponectin agonist, in type 2 diabetes and obesity. Int J Pharma Sci 2012; 16: 70-4.
[58]
Raman A, Lau C. Anti-diabetic properties and phytochemistry of momordica charantia l. (cucurbitaceae). Phytomedicine 1996; 2: 349-62.
[59]
Tripathy V, Verma J. Different models used to induce diabetes: A comprehensive review. Int J Pharm Pharm Sci 2014; 6: 29-32.
[60]
Kumar S, Singh R, Vasudeva N, Sharma S. Acute and chronic animal models for the evaluation of anti-diabetic agents. Cardiovasc Diabetol 2012; 11: 1-13.
[61]
King AJF. The use of animal models in diabetes research. Br J Pharmacol 2012; 166: 877-94.
[62]
Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: An overview. Indian J Med Res 2007; 451-72.
[63]
Karthikeyan M, Balasubramanian T, Kumar P. In-vivo animal models and in-vitro techniques for screening antidiabetic activity. Journal of developing drugs 2016; 5: 1-6.
[64]
Cowan MM. Plant products as antimicrobial agents. Clin Microbiol Rev 1999; 2: 564-82.
[65]
Basnet P, Basnet NS. Curcumin: An anti-inflammatory molecules from a curry spice on the path to cancer treatment. Molecules 2011; 16: 4567-98.
[66]
Khanna P, Nag TN, Chandrajaia S, Mohan SV. Process for isolation of insulin from plant source. United States Patent 1976; 3: 945-88.
[67]
McCarty MF. Does bitter melon contain an activator of AMP-activated kinase. Med Hypotheses 2004; 63: 340-3.
[68]
Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001; 50: 536-46.
[69]
Ku SK, Sung SH, Choung JJ, Choi JS, Shin YK, Kim JW. Anti-obesity and anti-diabetic effects of a standardized potato extract in ob/ob mice. Exp Ther Med 2016; 12: 354-64.
[70]
Etuk EU. Animals models for studying diabetes mellitus. Agriculture and Biology Journal of North America 2010; 1: 130-4.
[71]
Sharad S, Dwivedi J, Jha AK, Swapnil S. Experimental models of mice diabetes. Int J Res Ayurveda Pharm 2010; 1: 292-301.
[72]
Lenzen S. The mechanisms of alloxan and streptozotocin-induced diabetes. Diabetologia 2008; 51: 216-26.
[73]
Uebanso T, Arai H, Taketani Y, et al. Extracts of momordica charantia suppress postprandial hyperglycemia in rats. J Nutr Sci Vitaminol (Tokyo) 2007; 53: 482-8.
[74]
Kupsal K, Mudigonda S, Sai NVBK, Neelala K. Hanumanth. Metformin combinational therapy for type 2 diabetes mellitus. J of Metab Syndr 2016; 5: 1-8.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 19
ISSUE: 1
Year: 2019
Page: [12 - 19]
Pages: 8
DOI: 10.2174/1566524019666190219124301
Price: $65

Article Metrics

PDF: 21
HTML: 5
EPUB: 1

Special-new-year-discount